80 FR 57379 - National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 80, Issue 184 (September 23, 2015)
National Institutes of Health
Federal Register Volume 80, Issue 184 (September 23, 2015)
| Page Range | 57379-57380 | |
| FR Document | 2015-24117 |
[Federal Register Volume 80, Number 184 (Wednesday, September 23, 2015)] [Notices] [Pages 57379-57380] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-24117] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations SUMMARY: The Office of the Secretary of the Department of Health and Human Services (HHS) is seeking nominations for an individual to serve as a non-federal public member on the Muscular Dystrophy Coordinating Committee. DATES: Nominations are due by 5 p.m., October 26, 2015. ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email to [email protected]. FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to [email protected]. SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory committee established in accordance with the Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD- CARE Act was reauthorized in 2008 by Public Law 110-361, and again in 2014 by Public Law 113-166. The MD-CARE Act specifies that the committee membership be composed of \2/3\ governmental agency representatives and \1/3\ public members. We are seeking nominations for a non-federal, public member at this time, due to turnover of committee membership. Nominations will be accepted between September 25, 2015 and October 26, 2015. Who is Eligible: Nominations for a new non-federal public member interested in providing the public and/or patient perspective are encouraged. Self-nominations and nominations of other individuals are both permitted. Only one nomination per individual is required. Multiple nominations for the same individual will not increase likelihood of selection. Non-federal, public members may be selected from the pool of submitted nominations or other sources as needed to meet statutory requirements and to form a balanced committee that represents the diversity within the muscular dystrophy communities. Those eligible for nomination include leaders or representatives of major muscular dystrophy research, advocacy, and service organizations, parents or guardians of individuals with muscular dystrophy, individuals with muscular dystrophy, educators, researchers, and other individuals with professional or personal experience with muscular dystrophy. In accordance with White House Office of Management and Budget guidelines (FR Doc. 2014-19140), federally-registered lobbyists are not eligible. Committee Composition: The Department strives to ensure that the membership of HHS Federal advisory committees is fairly balanced in terms of points of view represented and the committee's function. Every effort is made to ensure that the views of all genders, all ethnic and racial groups, and people with disabilities are represented on HHS Federal advisory committees and, therefore, the Department encourages nominations of qualified candidates from these groups. The Department also encourages geographic diversity in the composition of the Committee. Appointment to this Committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. Requests for reasonable accommodation to enable participation on the Committee should be indicated in the nomination submission. Member Terms: Non-Federal public members of the Committee serve for a term of 3 years, and may serve for an unlimited number of terms if reappointed. Members may serve after the expiration of their terms, until their successors have taken office. Meetings and Travel: As specified by Public Law 113-166, the MDCC ``shall meet no fewer than two times per calendar year.'' Travel expenses are provided for non-federal public Committee members to facilitate attendance at in-person meetings. Members are expected to make every effort to attend all full committee meetings, twice per year, either in person or via remote access. Participation in relevant subcommittee, working and planning group meetings, and workshops, is also encouraged. Submission Instructions and Deadline: Nominations are due by 5 p.m. EST on October 26, 2015, and should be sent to Glen Nuckolls, Ph.D., by email to [email protected]. Nominations must include contact information for the nominee, a current curriculum vitae or resume of the nominee and a paragraph describing the qualifications of the person to represent some portion(s) of the muscular dystrophy research, advocacy and/or patient care communities. More information about the MDCC is available at http://www.ninds.nih.gov/about_ninds/groups/mdcc/. [[Page 57380]] Dated: September 16, 2015. Walter J. Koroshetz, Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health. [FR Doc. 2015-24117 Filed 9-22-15; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices 57379
Review Group; Macromolecular Structure DEPARTMENT OF HEALTH AND other individuals with professional or
and Function D Study Section. HUMAN SERVICES personal experience with muscular
Date: October 15–16, 2015. dystrophy. In accordance with White
Time: 8:00 a.m. to 5:00 p.m. National Institutes of Health House Office of Management and
Agenda: To review and evaluate grant
applications and/or proposals. Budget guidelines (FR Doc. 2014–
National Institute of Neurological 19140), federally-registered lobbyists are
Place: Kinzie Hotel, 20 West Kinzie Street,
Chicago, IL 60654.
Disorders and Stroke, Muscular not eligible.
Contact Person: James W Mack, Ph.D., Dystrophy Coordinating Committee Committee Composition: The
Scientific Review Officer, Center for Call for Committee Membership Department strives to ensure that the
Scientific Review, National Institutes of Nominations membership of HHS Federal advisory
Health, 6701 Rockledge Drive, Room 4154, committees is fairly balanced in terms of
MSC 7806, Bethesda, MD 20892, (301) 435– SUMMARY: The Office of the Secretary of
the Department of Health and Human points of view represented and the
2037, mackj2@csr.nih.gov.
Services (HHS) is seeking nominations committee’s function. Every effort is
Name of Committee: Genes, Genomes, and made to ensure that the views of all
Genetics Integrated Review Group; Genetic for an individual to serve as a non-
Variation and Evolution Study Section. federal public member on the Muscular genders, all ethnic and racial groups,
Date: October 23, 2015. Dystrophy Coordinating Committee. and people with disabilities are
Time: 8:00 a.m. to 7:00 p.m. DATES: Nominations are due by 5 p.m.,
represented on HHS Federal advisory
Agenda: To review and evaluate grant October 26, 2015. committees and, therefore, the
applications. Department encourages nominations of
Place: Residence Inn Bethesda, 7335 ADDRESSES: Nominations must be sent
qualified candidates from these groups.
Wisconsin Avenue, Bethesda, MD 20814. to Glen Nuckolls, Ph.D., by email to The Department also encourages
Contact Person: Ronald Adkins, Ph.D., nuckollg@ninds.nih.gov. geographic diversity in the composition
Scientific Review Officer, Center for FOR FURTHER INFORMATION CONTACT: Glen
Scientific Review, National Institutes of of the Committee. Appointment to this
Nuckolls, Ph.D., by email to nuckollg@ Committee shall be made without
Health, 6701 Rockledge Drive, Room 2206,
ninds.nih.gov. discrimination on the basis of age, race,
MSC 7890, Bethesda, MD 20892, 301–435–
4511, ronald.adkins@nih.gov. SUPPLEMENTARY INFORMATION: The ethnicity, gender, sexual orientation,
Name of Committee: Center for Scientific Muscular Dystrophy Coordinating disability, and cultural, religious, or
Review Special Emphasis Panel; RFA Panel: Committee (MDCC) is a federal advisory socioeconomic status. Requests for
NIH–PEPFAR Collaboration on committee established in accordance reasonable accommodation to enable
Implementation Science for HIV. with the Muscular Dystrophy participation on the Committee should
Date: October 26–27, 2015. Community Assistance, Research, and be indicated in the nomination
Time: 9:00 a.m. to 5:00 p.m. Education Amendments of 2001 (MD– submission.
Agenda: To review and evaluate grant CARE Act; Pub. L. 107–84). The MD–
applications.
Member Terms: Non-Federal public
Place: Hyatt Regency Bethesda, One
CARE Act was reauthorized in 2008 by members of the Committee serve for a
Bethesda Metro Center, 7400 Wisconsin Public Law 110–361, and again in 2014 term of 3 years, and may serve for an
Avenue, Bethesda, MD 20814. by Public Law 113–166. The MD–CARE unlimited number of terms if
Contact Person: Shalanda A. Bynum, Act specifies that the committee reappointed. Members may serve after
Ph.D., MPH, Scientific Review Officer, Center membership be composed of 2⁄3 the expiration of their terms, until their
for Scientific Review, National Institutes of governmental agency representatives successors have taken office.
Health, 6701 Rockledge Drive Room 3206, and 1⁄3 public members. We are seeking Meetings and Travel: As specified by
Bethesda, MD 20892, 301–435–1165, nominations for a non-federal, public Public Law 113–166, the MDCC ‘‘shall
bynumsa@csr.nih.gov.
member at this time, due to turnover of meet no fewer than two times per
Name of Committee: Center for Scientific committee membership. Nominations
Review Special Emphasis Panel; Member
calendar year.’’ Travel expenses are
Conflict: Psychosocial and Developmental
will be accepted between September 25, provided for non-federal public
Risk and Disease Prevention. 2015 and October 26, 2015. Committee members to facilitate
Date: October 27, 2015. Who is Eligible: Nominations for a attendance at in-person meetings.
Time: 1:00 p.m. to 4:00 p.m. new non-federal public member Members are expected to make every
Agenda: To review and evaluate grant interested in providing the public and/ effort to attend all full committee
applications. or patient perspective are encouraged. meetings, twice per year, either in
Place: National Institutes of Health, 6701 Self-nominations and nominations of person or via remote access.
Rockledge Drive, Bethesda, MD 20892, other individuals are both permitted.
(Virtual Meeting). Participation in relevant subcommittee,
Only one nomination per individual is working and planning group meetings,
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for required. Multiple nominations for the and workshops, is also encouraged.
Scientific Review, National Institutes of same individual will not increase Submission Instructions and
Health, 6701 Rockledge Drive, Room 3100, likelihood of selection. Non-federal, Deadline: Nominations are due by 5
MSC 7808, Bethesda, MD 20892, (301) 594– public members may be selected from p.m. EST on October 26, 2015, and
3292, niw@csr.nih.gov. the pool of submitted nominations or should be sent to Glen Nuckolls, Ph.D.,
(Catalogue of Federal Domestic Assistance other sources as needed to meet by email to nuckollg@ninds.nih.gov.
Program Nos. 93.306, Comparative Medicine; statutory requirements and to form a Nominations must include contact
93.333, Clinical Research, 93.306, 93.333, balanced committee that represents the information for the nominee, a current
93.337, 93.393–93.396, 93.837–93.844, diversity within the muscular dystrophy curriculum vitae or resume of the
93.846–93.878, 93.892, 93.893, National
mstockstill on DSK4VPTVN1PROD with NOTICES
Institutes of Health, HHS)
communities. Those eligible for nominee and a paragraph describing the
nomination include leaders or qualifications of the person to represent
Dated: September 18, 2015. representatives of major muscular some portion(s) of the muscular
David Clary, dystrophy research, advocacy, and dystrophy research, advocacy and/or
Program Analyst, Office of Federal Advisory service organizations, parents or patient care communities.
Committee Policy. guardians of individuals with muscular More information about the MDCC is
[FR Doc. 2015–24202 Filed 9–22–15; 8:45 am] dystrophy, individuals with muscular available at http://www.ninds.nih.gov/
BILLING CODE 4140–01–P dystrophy, educators, researchers, and about_ninds/groups/mdcc/.
VerDate Sep<11>2014 18:00 Sep 22, 2015 Jkt 235001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\23SEN1.SGM 23SEN1](https://thefederalregister.org/doc/80_FR_57563/page/1.svg)
![57380 Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
Dated: September 16, 2015. minutes, is highly efficient, and has low A Mobile Health Platform
Walter J. Koroshetz, background. Description of Technology: The NIH
Director, National Institute of Neurological Potential Commercial Applications inventors have developed a mobile
Disorders and Stroke, National Institutes of health technology to monitor and
Health. • A rapid assay for point-of-care
predict a user’s psychological status and
[FR Doc. 2015–24117 Filed 9–22–15; 8:45 am] diagnosis of infectious and autoimmune
to deliver an automated intervention
BILLING CODE 4140–01–P diseases.
when needed. The technology uses
• Applications to different assay
smartphones to monitor the user’s
platforms, such as a portable,
location and ask questions about
DEPARTMENT OF HEALTH AND commercially available hand-held
psychological status throughout the day.
HUMAN SERVICES luminometer or an automated, high-
Continuously collected ambulatory
throughput device.
National Institutes of Health psychological data are fused with data
Competitive Advantages on location and responses to questions.
Government-Owned Inventions; • Highly efficient, rapid, and easy to The mobile data are combined with
Availability for Licensing perform. geospatial risk maps to quantify
• Low background signals. exposure to risk and predict a future
AGENCY: National Institutes of Health, psychological state. The future
HHS. Development Stage predictions are used to warn the user
ACTION: Notice. • Early-stage when he or she is at especially high risk
SUMMARY: The inventions listed below • In vitro data available of experiencing a negative event that
are owned by an agency of the U.S. • Prototype. might lead to an unwanted outcome
Inventor: Peter D. Burbelo (NIDCR) (e.g., lapse to drug use in a recovering
Government and are available for addict).
licensing in the U.S. in accordance with Publications An internally developed mobile app
35 U.S.C. 209 and 37 CFR part 404 to is now being deployed to deliver an
achieve expeditious commercialization 1. Burbelo PD, et al. Luciferase
immunoprecipitation systems for measuring intervention in the context of drug
of results of federally-funded research addiction. The inventors are also
antibodies in autoimmune and infectious
and development. Foreign patent diseases. Transl Res. 2015 Feb; 165(2):325– seeking to test the technology for other
applications are filed on selected 335. [PMID 25241936] health applications.
inventions to extend market coverage 2. Burbelo PD, et al. New autoantibody
for companies and may also be available detection technologies yield novel insights Potential Commercial Applications
for licensing. into autoimmune disease. Curr Opin • Real time behavior monitoring
FOR FURTHER INFORMATION CONTACT: Rheumatol. 2014 Nov; 26(6):717–723. [PMID • Therapeutic delivery of an
25203116] intervention via a mobile device
Licensing information and copies of the
3. Burbelo PD, et al. Searching for
U.S. patent applications listed below biomarkers: humoral response profiling with Competitive Advantages
may be obtained by writing to the luciferase immunoprecipitation systems.
indicated licensing contact at the Office Expert Rev Proteomics. 2011 Jun; 8(3):309– • Mobile device
of Technology Transfer, National 316. [PMID 21679112] • Real time
Institutes of Health, 6011 Executive 4. Burbelo PD, et al. Antibody profiling by • Exposure to risk
Boulevard, Suite 325, Rockville, luciferase immunoprecipitation systems Development Stage: Prototype
Maryland 20852–3804; telephone: 301– (LIPS). J Vis Exp. 2009 Oct 7; (32). [PMID Inventors: Kenzie L. Preston, David H.
496–7057; fax: 301–402–0220. A signed 19812534] Epstein, Matthew Tyburski, Massoud
Confidential Disclosure Agreement will Intellectual Property: HHS Reference Vahabzadeh (all of NIDA)
be required to receive copies of the No. E–190–2015/0—US Provisional Publications
patent applications. Application No. 62/212,973 filed 01 Oct
2015. 1. Epstein DH, et al. Real-time tracking of
SUPPLEMENTARY INFORMATION:
neighborhood surroundings and mood in
Technology descriptions follow. Related Technologies urban drug misusers: Application of a new
A Novel Rapid Point-of-Care Diagnostic method to study behavior in its geographical
• E–036–2010 family: PCT/US2011/ context. Drug Alcohol Depend. 2014 Jan
Method for Infectious and Autoimmune 027888, US 8,926,989, issued. US 14/ 1;134:22–9. [PMID 24332365]
Diseases 562,068 and EP 11730770.1, pending. 2. Kennedy AP, et al. Continuous in-the-
Description of Technology: Rapid • E–281–2010: US 13/882,850, field measurement of heart rate: Correlates of
point-of-care, antibody-based testing is allowed. drug use, craving, stress and mood in
not available for the diagnosis of • E–063–2009: US 8,951,723, issued. polydrug users. Drug Alcohol Depend. 2015
autoimmune and most infectious Licensing Contact: Sally Hu, Ph.D., June 1;151:159–66. [PMID 25920802]
diseases. For detecting autoantibodies M.B.A.; 301–435–5606; hus@ Intellectual Property: HHS Reference
associated with most autoimmune mail.nih.gov. No. E–049–2015/0—US Provisional
conditions, fluid-phase Collaborative Research Opportunity: Application No. 62/186, 983 filed 30
immunoprecipitation assays are The National Institute of Dental and June 2015
required. However, these assays usually Craniofacial Research is seeking Licensing Contact: Betty B. Tong,
mstockstill on DSK4VPTVN1PROD with NOTICES
involve radioactivity and are not statements of capability or interest from Ph.D.; 301–594–6565; tongb@
feasible for point-of-care applications. parties interested in collaborative mail.nih.gov
The subject invention describes research to further develop, evaluate or Collaborative Research Opportunity:
methods of using neodymium magnet commercialize using neodymium The National Institute on Drug Abuse is
for diagnosis of infectious and magnet for rapid diagnosis. For seeking statements of capability or
autoimmune diseases including lupus, collaboration opportunities, please interest from parties interested in
Sjögren’s syndrome, type I diabetes, HIV contact David Bradley, Ph.D. at collaborative research to further
and Lyme disease. The assay takes 3.5 bradleyda@nidcr.nih.gov. develop, evaluate or commercialize
VerDate Sep<11>2014 18:00 Sep 22, 2015 Jkt 235001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 E:\FR\FM\23SEN1.SGM 23SEN1](https://thefederalregister.org/doc/80_FR_57563/page/2.svg)
Document Created: 2015-12-15 09:45:29
Document Modified: 2015-12-15 09:45:29
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | Nominations are due by 5 p.m., October 26, 2015. | |
| Contact | Glen Nuckolls, Ph.D., by email to [email protected] | |
| FR Citation | 80 FR 57379 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR